5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoSkin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligoActive, not recruitingPhase 32026-09-28NCT06163326
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderRecruitingPhase 32026-09-25NCT06807281
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaSkin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, skin disorderRecruitingPhase 32026-09-25NCT06807268
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisActive, not recruitingPhase 32026-06-02NCT06550076
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderRecruitingPhase 22026-05-04NCT05995964